Navigation Links
SmartGene, Inc. Enters Collaboration with Virco Lab, Inc. to Enhance HIV Genotyping and Resistance Interpretation Services in US
Date:4/20/2009

RALEIGH, N.C., April 20 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and analysis of genetic data, today announced a marketing and distribution collaboration with Virco Lab, Inc., to help US laboratories manage, analyze, and derive maximum benefit from their HIV sequences. Virco will market SmartGene, Inc.'s secure, Web-based service module, SmartGene(R) HIV, which is a unique, integrated, data management solution encompassing various interpretation algorithms, multiple genetic targets and cumulative resistance reporting.

The SmartGene HIV platform will allow laboratories using both SmartGene, Inc. and Virco services to send an order for interpretation of sequence data by Virco directly out of the SmartGene HIV module and then store the resulting virco(R)TYPE HIV-1 resistance reports within their SmartGene database.

"HIV clinicians and laboratorians understand the importance of longitudinal data to resistance assessment; they value the insight gained from reinterpreting sequences with updated algorithms and comparing results derived from different algorithms; they are interested in analyzing new genetic targets, such as Integrase and Envelope. SmartGene HIV exquisitely meets these needs," said David Ellis, President of SmartGene, Inc. "We have made excellent progress introducing our modules supporting bacterial and fungal identification by sequence analysis. As we expand the deployment of our services for virology in the US, we are delighted to enter this collaboration with Virco, a long-standing market leader for resistance testing and interpretation in the HIV field."

About SmartGene, Inc.

SmartGene, Inc. is the North American subsidiary of SmartGene GmbH, a privately-held company based in Zug, Switzerland, which provides its services worldwide. SmartGene provides web-based suites of functionality to facilitate sequence-based analysis for a variety of clinical, medical research, and veterinary applications. Constant updates to reference data and interpretive algorithms keep SmartGene's customers in step with evolving science and improve the accuracy of sequence interpretation. SmartGene's integrated services increase the speed to result for sequence-based diagnostics and improve workflow in the laboratory. Current modules from SmartGene include Bacteria, Fungi, HIV, HCV, MLST, Influenza, and HLA typing. Future applications will address human genetics as well as food and environmental pathogens. Discover more at www.smartgene.com.


'/>"/>
SOURCE SmartGene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
(Date:1/11/2017)... 2017  Brian Mehling, M.D., world-renowned stem cell researcher, ... International (BHI), will be attending the 47th Annual World ... from January 17-20, 2017. This will be Dr. Mehling,s ... theme of this year,s forum is Responsive and Responsible ... address strategies for fostering greater social inclusion and human ...
(Date:1/11/2017)... ... 2017 , ... IsoPlexis Corporation (IsoPlexis), a venture-capital ... the proteomic function of individual cells in patients, today announced it was recently ... National Institute on Aging of the National Institutes of Health to develop a ...
(Date:1/11/2017)... ... January 11, 2017 , ... Advanced Polymer ... its team. Bernhard Bartylla will lead European initiatives for APMT’s product lines serving ... ACOMP and ARGEN to European manufacturers and researchers. Bernhard brings significant experience in ...
Breaking Biology Technology:
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):